

Disease-Modifying Therapies (DMT) Market - 2025-2033

<https://marketpublishers.com/r/D4117BF18FDBEN.html>

Date: March 2026

Pages: 186

Price: US\$ 2,999.00 (Single User License)

ID: D4117BF18FDBEN

Abstracts

The Disease-Modifying Therapies (DMT) Market was valued at US\$ 165.88 Billion in 2025 and is anticipated to reach US\$ 281.88 Billion by 2033, at a CAGR of 0.0643 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Disease-Modifying Therapies (DMT) Market.

This report delivers a comprehensive overview of the Disease-Modifying Therapies (DMT) Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Disease-Modifying Therapies (DMT) Market. The Disease-Modifying Therapies (DMT) Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2025–2033.

Disease-Modifying Therapies (DMT) Market Scope:

Key Players

Genentech USA, Inc.

Novartis, AG.

Teva Neuroscience, Inc.

GSK

AstraZeneca

Johnson & Johnson

AbbVie Inc.

Amgen Inc.

UCB, Inc.

Takeda Pharmaceuticals U.S.A., Inc.

Major Highlights

This report delivers a comprehensive overview of the Disease-Modifying Therapies (DMT) Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Disease-Modifying Therapies (DMT) Market. The Disease-Modifying Therapies (DMT) Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2025–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. MARKET INTRODUCTION AND SCOPE

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

- 2.1. Market Highlights and Strategic Takeaways
- 2.2. Key Trends and Future Projections
- 2.3. Snippet by Drug Class
- 2.4. Snippet by Disease Indication
- 2.5. Snippet by Route of Administration
- 2.6. Snippet by Distribution Channel
- 2.7. Snippet by Region

3. DYNAMICS

- 3.1. Impacting Factors
 - 3.1.1. Drivers
 - 3.1.1.1. Rising Disease Prevalence and Earlier Diagnosis
 - 3.1.1.2. Entry of Novel Biologics and Oral Therapies
 - 3.1.2. Restraints
 - 3.1.2.1. Safety Concerns, Long-Term Efficacy, and Adherence Issues
 - 3.1.2.2. High Cost of Therapy and Access Inequities
 - 3.1.3. Opportunity
 - 3.1.3.1. Next-Generation Therapies and Modalities
 - 3.1.3.2. Biosimilars and Cost-Effective Alternatives

4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

- 4.1. Market Leaders and Pioneers
 - 4.1.1. Emerging Pioneers and Prominent Players
 - 4.1.2. Established Leaders with the Largest Marketing Brand
 - 4.1.3. Market Leaders with Established Products
- 4.2. Latest Developments and Breakthroughs
- 4.3. Regulatory and Reimbursement Landscape

- 4.3.1. North America
- 4.3.2. Europe
- 4.3.3. Asia Pacific
- 4.3.4. South America
- 4.3.5. Middle East & Africa
- 4.4. Porter's Five Forces Analysis
 - 4.4.1. Bargaining Power of Suppliers
 - 4.4.2. Bargaining Power of Buyers
 - 4.4.3. Threat of Substitutes
 - 4.4.4. Threat of New Entrants
 - 4.4.5. Competitive Rivalry
- 4.5. Patent Analysis
 - 4.5.1. Patent Expiry and Exclusivity
 - 4.5.2. Key Patent Holders
 - 4.5.3. Patent Litigations
 - 4.5.4. Licensing Opportunities
- 4.6. Unmet Needs and Gaps
- 4.7. Recommended Strategies for Market Entry and Expansion
- 4.8. Pricing Analysis and Price Dynamics
 - 4.8.1. Price Benchmarking vs. Competitors
 - 4.8.2. Reimbursement Landscape
 - 4.8.3. Pricing Trends by Region or Segment
 - 4.8.4. Value-Based Pricing Opportunities
- 4.9. SWOT Analysis
 - 4.9.1. Strengths: Internal Advantages
 - 4.9.2. Weaknesses: Internal Limitations
 - 4.9.3. Opportunities: External Growth Possibilities
 - 4.9.4. Threats: External Challenges
- 4.10. Supply Chain Analysis
 - 4.10.1. Raw Material Sourcing
 - 4.10.2. Manufacturing Locations
 - 4.10.3. Distribution Channels
 - 4.10.4. Logistics and Transportation
 - 4.10.5. Supplier Risk Assessment

5. DISEASE-MODIFYING THERAPIES MARKET, BY DRUG CLASS

5.1. Introduction

- 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

- 5.1.2. Market Attractiveness Index, By Drug Class
- 5.2. Biologics*
 - 5.2.1. Introduction
 - 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
 - 5.2.3. Monoclonal Antibodies
 - 5.2.4. Interferons
- 5.3. Small Molecule Drugs
 - 5.3.1. Kinase Inhibitors
 - 5.3.2. Immunomodulators

6. DISEASE-MODIFYING THERAPIES MARKET, BY DISEASE INDICATION

- 6.1. Introduction
 - 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
 - 6.1.2. Market Attractiveness Index, By Disease Indication
- 6.2. Multiple Sclerosis*
 - 6.2.1. Introduction
 - 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Rheumatoid Arthritis
- 6.4. Lupus
- 6.5. Crohn's Disease
- 6.6. Other

7. DISEASE-MODIFYING THERAPIES MARKET, BY ROUTE OF ADMINISTRATION

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 7.1.2. Market Attractiveness Index, By Route of Administration
- 7.2. Parenteral*
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Oral

8. DISEASE-MODIFYING THERAPIES MARKET, BY DISTRIBUTION CHANNEL

- 8.1. Introduction
 - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 8.1.2. Market Attractiveness Index, By Distribution Channel

8.2. Hospital Pharmacies*

8.2.1. Introduction

8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

8.3. Retail Pharmacies

9. DISEASE-MODIFYING THERAPIES MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

9.1. Introduction

9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

9.1.2. Market Attractiveness Index, By Region

9.2. North America

9.2.1. Introduction

9.2.2. Key Region-Specific Dynamics

9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication

9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.2.7.1. U.S.

9.2.7.2. Canada

9.2.7.3. Mexico

9.3. Europe

9.3.1. Introduction

9.3.2. Key Region-Specific Dynamics

9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication

9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.3.7.1. Germany

9.3.7.2. UK

9.3.7.3. France

9.3.7.4. Spain

9.3.7.5. Italy

9.3.7.6. Rest of Europe

9.4. Asia-Pacific

9.4.1. Introduction

9.4.2. Key Region-Specific Dynamics

9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication

9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.4.7.1. China

9.4.7.2. India

9.4.7.3. Japan

9.4.7.4. South Korea

9.4.7.5. Rest of Asia-Pacific

9.5. South America

9.5.1. Introduction

9.5.2. Key Region-Specific Dynamics

9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication

9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.5.7.1. Brazil

9.5.7.2. Argentina

9.5.7.3. Rest of South America

9.6. Middle East and Africa

9.6.1. Introduction

9.6.2. Key Region-Specific Dynamics

9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication

9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

10.1. Competitive Overview and Key Market Players

10.2. Market Share Analysis and Positioning Matrix

10.3. Strategic Partnerships, Mergers & Acquisitions

10.4. Key Developments in Product Portfolios and Innovations

10.5. Company Benchmarking

11. COMPANY PROFILES

11.1. Genentech USA, Inc.*

11.1.1. Company Overview

11.1.2. Product Portfolio

11.1.2.1. Product Description

11.1.2.2. Product Key Performance Indicators (KPIs)

11.1.3. Financial Overview

11.1.3.1. Company Revenue

11.1.3.2. Geographical Revenue Shares

11.1.3.3. Revenue Forecasts

11.1.4. Key Developments

11.1.4.1. Mergers & Acquisitions

11.1.4.2. Key Product Development Activities

11.1.4.3. Regulatory Approvals, etc.

11.1.4.4. SWOT Analysis

11.2. Novartis, AG.

11.3. Teva Neuroscience, Inc.

11.4. GSK

11.5. AstraZeneca

11.6. Johnson & Johnson

11.7. AbbVie Inc.

11.8. Amgen Inc.

11.9. UCB, Inc.

11.10. Takeda Pharmaceuticals U.S.A., Inc. (LIST NOT EXHAUSTIVE)

12. ASSUMPTIONS AND RESEARCH METHODOLOGY

12.1. Data Collection Methods

12.2. Data Triangulation

12.3. Forecasting Techniques

12.4. Data Verification and Validation

13. APPENDIX

13.1. About Us and Services

13.2. Contact Us

I would like to order

Product name: Disease-Modifying Therapies (DMT) Market - 2025-2033

Product link: <https://marketpublishers.com/r/D4117BF18FDBEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D4117BF18FDBEN.html>